Xiangxue Pharmaceutical Co.,Ltd. (SHE:300147)
China flag China · Delayed Price · Currency is CNY
6.33
-0.23 (-3.51%)
Sep 23, 2026, 3:04 PM CST

Xiangxue Pharmaceutical Financials Overview

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Revenue
1,4801,5951,8592,2992,1872,971
Revenue Growth
-6.32%-14.16%-19.16%5.13%-26.38%-3.30%
Gross Profit
434.65422.89407.61743.33533.38741.4
Operating Income
-39.92-102.06-233.9249.67-175.35-22.39
Net Income
-1,427-1,392-858.56-388.96-530.06-688.47
Earnings Per Share
-2.18-2.11-1.30-0.59-0.80-1.04
EPS Growth
------

Revenue by Segment

Fiscal YearFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '24 Dec '23 Jan '23 Jan '22
Pharmaceutical Distribution
75.61252.4360.36588.12868.86
Pharmaceutical Manufacturing
430.57302.7825.29384.52475.2
Others
357.75347.37351.47273.85170.5
Offset of Business Segment
-278.26----
Medical Instruments
1920.0917.4216.214.8
Chinese Herbal Medicines
990.74936.1744.75924.371,209
Total
1,5951,8592,2992,1872,971

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Investments
177.41254.57144.74149.32166.63367.17
Total Debt
1,4371,4672,2432,4332,4583,448
Net Cash (Debt)
-1,260-1,212-2,098-2,284-2,291-3,081
Net Cash Growth
------
Net Cash Per Share
-1.93-1.84-3.18-3.46-3.46-4.65

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Cash Flow
98.15139.6318.17263.44227.38257.56
Capital Expenditures
-27.68-21.51-35.24-56.03-367.27-562.74
Free Cash Flow
70.46118.12-17.07207.41-139.89-305.18
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Gross Margin
29.37%26.51%21.93%32.33%24.39%24.96%
Operating Margin
-2.70%-6.40%-12.58%2.16%-8.02%-0.75%
Pretax Margin
-91.68%-83.79%-45.31%-16.92%-23.40%-21.40%
Profit Margin
-96.41%-87.26%-46.19%-16.92%-24.24%-23.18%
FCF Margin
4.76%7.40%-0.92%9.02%-6.40%-10.27%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Forward PE
-11.9311.9311.9311.9311.93
P/FCF Ratio
59.4150.95-16.42--
PS Ratio
2.833.773.481.481.811.77